Advanced, metastatic or recurrent olaparib |
Low |
February 2023 |
Ovarian advanced cARBOplatin and DOCEtaxel |
Medium |
February 2027 |
Ovarian advanced cARBOplatin and PACLItaxel three weekly |
Medium |
February 2026 |
Ovarian advanced cARBOplatin and PACLItaxel weekly |
Medium |
February 2024 |
Ovarian advanced cARBOplatin three weekly and PACLitaxel weekly |
Medium |
February 2026 |
Ovarian advanced cARBOplatin PACLItaxel and bevacizumab |
Medium (moves to low risk after completion of cARBOplatin/PACLitaxel treatment)
|
February 2027 |
Ovarian advanced combined intravenous and intraperitoneal cISplatin and PACLItaxel |
High |
February 2024 |
Ovarian advanced
or recurrent niraparib
|
Low |
February 2024 |
Ovarian advanced primary treatment cARBOplatin |
Medium |
February 2027 |
Ovarian dysgerminoma advanced or metastatic BEP (bleomycin etoposide cISplatin) |
Medium |
February 2027 |
Ovarian high risk stage 1 adjuvant cARBOplatin and PACLItaxel |
Medium |
February 2025 |
Ovarian recurrent cARBOplatin |
Medium |
February 2027 |
Ovarian recurrent cARBOplatin and DOXOrubicin pegylated liposomal |
Medium |
February 2027 |
Ovarian recurrent cARBOplatin and gemcitabine (day 1 cARBOplatin) |
Medium - Day 1. Low - Day 8 |
February 2027 |
Ovarian recurrent cARBOplatin, gemcitabine and beVACizumab |
Medium |
February 2027 |
Ovarian recurrent DOXOrubicin pegylated liposomal |
Medium |
February 2027 |
Ovarian recurrent DOXOrubicin pegylated liposomal and beVACizumab |
Medium |
February 2027 |
Ovarian recurrent gemcitabine |
Low |
February 2027 |
Ovarian recurrent niraparib |
Low |
February 2027 |
Ovarian recurrent PACLItaxel weekly |
Medium |
February 2027 |
Ovarian recurrent PACLitaxel weekly and beVACizumab |
Medium |
February 2027 |
Ovarian recurrent topotecan (modified) three weekly |
Medium |
February 2027 |